Ibrutinib + Rituximab for Chronic Lymphocytic Leukemia

"From what is available on clinicaltrials.gov, it seems as if this study has stopped looking for patients to participate. The original posting was on February 20th, 2014 with the most recent edit being on September 23rd, 2022. Even though this specific trial is no longer running, there are 4483 other trials that are still trying to recruit patients."

"Ibrutinib is a medication that, while typically used to treat lung cancer, can also be used for b-cell lymphomas, polyangium, and multiple sclerosis."

"The primary outcome of this study, which will be evaluated over a Baseline to 12 months after beginning therapy time frame is to Progression free survival (PFS). Secondary outcomes include Change in FACT-Leu TOI score, Overall survival (OS), and Impact of chronic lymphocytic leukemia (CLL) on QOL."

"Ibrutinib has been evaluated for safety in multiple Phase 3 trials, meaning that there is both efficacy and safety data available. Our team rates it as a 3 on our 1 to 3 scale."

"Ibrutinib is being studied in 1314 different clinical trials at the moment. Of those, 239 are in Phase 3. Although a majority of the trials for Ibrutinib are taking place in Philadelphia, Pennsylvania, there are 40806 locations running studies for this treatment across the globe."

"As this study's eligibility requirements indicate, the minimum age for participants is 18 while the maximum is 70."

"There are 100 available for this trial. They are located at The Don and Sybil Harrington Cancer Center in Amarillo, Duly Health and Care Joliet in Joliet, New Ulm Medical Center in New Ulm, and many other places."

"Unfortunately, this trial is not looking for new patients at the moment. Although, it's important to note that the study was last updated on September 23rd, 2022. If you're interested in other anemia trials or Ibrutinib trials, there are 3169 and 1314 studies recruiting respectively."

"519 anemic patients between the ages of 18 and 70 who meet the following additional criteria are eligible for enrollment in this study: The predominant population of lymphocytes share both B-cell antigens (cluster of differentiation [CD]19, CD20 [typically dim expression], or CD23) as well as CD5 in the absence of other pan-T-cell markers (CD3, CD2, etc), Fevers > 100.5 Fahrenheit (F) for 2 weeks without evidence of infection, Symptomatic or progressive lymphadenopathy, splenomegaly, or hepatomegaly, Weight loss >="